Wockhardt Ltd

{"description":"Wockhardt said its Zaynich antibiotic could peak at $1.5 billion in sales, with a US launch targeted by year-end and an India launch planned around the same time.","url":"https://www.business-standard.com/companies/news/wockhardt-eyes-1-5-bn-peak-sales-from-zaynich-targets-us-launch-by-yr-end-126060101837_1.html","sentiment":"Positive","domain":"Business Standard"}

{"description":"Wockhardt shares rose after USFDA approved Zaynich (WCK 5222), a novel antibiotic for complicated UTIs, making it India’s first indigenously discovered drug cleared in the US.","url":"https://www.cnbctv18.com/market/wockhardt-share-price-usfda-approval-key-breakthrough-drug-antibiotic-wck-5222-zaynich-urinary-tract-infections-ws-l-19916824.htm","sentiment":"Positive","domain":"CNBCTV18"}

{"description":"Wockhardt shares jumped up to 16% after the US FDA cleared its novel antibiotic Zaynich, a key regulatory milestone that could boost the drugmaker's US pipeline.","url":"https://www.moneycontrol.com/news/business/markets/wockhardt-stock-soars-up-to-16-as-us-fda-clears-novel-antibiotic-zaynich-13937078.html","sentiment":"Positive","domain":"Moneycontrol"}

{"description":"Wockhardt jumped 19% after USFDA approved Zaynich (cefepime and zidebactam), a novel IV antibiotic for serious infections, fueling a 75% monthly rally in the pharma stock.","url":"https://www.business-standard.com/markets/news/wockhardt-soars-19-zooms-75-in-1-month-what-s-driving-pharma-stock-126060100520_1.html","sentiment":"Positive","domain":"Business Standard"}

{"description":"Wockhardt rose 11.55% to Rs 2,266.10 after the U.S. FDA approved its novel antibiotic ZAYNICH, a regulatory win that could support future drug commercialization.","url":"https://www.business-standard.com/markets/capital-market-news/wockhardt-rallies-after-u-s-fda-clears-novel-antibiotic-zaynich-126060100536_1.html","sentiment":"Positive","domain":"Business Standard"}

{"description":"Wockhardt gained focus after USFDA approved Zaynich, its IV antibiotic for complicated UTIs in adults; the drug had earlier received QIDP and Fast Track designations.","url":"https://www.news18.com/business/markets/stocks-to-watch-today-indigo-cyient-wockhardt-nmdc-olectra-greentech-remain-in-focus-on-june-1-ws-l-10123220.html","sentiment":"Positive","domain":"CNN-News18"}

{"description":"Wockhardt rose over 9% after CDSCO approved import and marketing of Zaynich in India for adult cUTI, including pyelonephritis and Gram-negative bacteremia, backed by Phase 3 data.","url":"https://www.cnbctv18.com/market/wockhardt-shares-jump-9-after-cdsco-approves-breakthrough-antibiotic-zaynich-in-india-ws-l-19915377.htm","sentiment":"Positive","domain":"CNBCTV18"}

{"description":"Wockhardt said CDSCO has approved import and marketing of Zaynich (zidebactam/cefepime) in India for adults with complicated UTI, backed by Phase 3 ENHANCE-1 trial data.","url":"https://money.rediff.com/news/market/wockhardt-zaynich-antibiotic-gets-cdsco-approval/47838920260528","sentiment":"Positive","domain":"money.rediff"}

{"description":"Wockhardt shares jumped 12.55% to a 9-month high after the company reported a Q4FY26 net profit of ₹164 crore, reversing losses and boosting investor sentiment.","url":"https://www.msn.com/en-in/money/markets/wockhardt-shares-surge-over-12-to-9-month-high-as-company-swings-to-profit-in-q4/ar-AA22q2ye?ocid=BingNewsVerp","sentiment":"Positive","domain":"Mint on MSN"}

{"description":"Wockhardt surged over 10% after Q4FY26 results showed revenue up 30% to ₹965 crore, a ₹166 crore profit versus a ₹25 crore loss, and margins expanding to 23.3%.","url":"https://www.cnbctv18.com/market/wockhardt-share-price-jumps-profitability-returns-in-q4-margins-expand-on-revenue-growth-ws-l-19898957.htm","sentiment":"Positive","domain":"CNBCTV18"}